In a high-stakes corporate battle, Pfizer has successfully acquired obesity biotech company Metsera, capping off a whirlwind bidding war that gained public attention just over a week ago. The acquisition agreement, valued at up to $86.25 per share, includes $65.60 in cash upfront and a contingent value right of up to $20.65, bringing the overall potential worth of the deal to over $10 billion, according to reports from The Wall Street Journal.
Initially, the two companies had agreed on a transaction worth approximately $7.3 billion in late September. However, the landscape shifted dramatically when Danish pharmaceutical giant Novo Nordisk entered the fray with a bid that escalated to nearly $9 billion, prompting a flurry of legal actions as the competition intensified.
Behind the scenes, both Pfizer and Novo Nordisk were engaged in a back-and-forth regarding their offers, sparking concerns over the legality and regulatory implications of the various proposals. Crucially, the Federal Trade Commission (FTC) intervened, expressing apprehension regarding Novo Nordisk’s approach. An official from the FTC reached out shortly before the deal announcement, advising both Metsera and Novo Nordisk about potential risks associated with the deal structure proposed by Novo. As a result, Metsera’s board concluded that engaging with Novo’s offer would present “unacceptably high legal and regulatory risks.”
In light of these developments, Novo Nordisk issued a statement confirming that it would not be increasing its offer for Metsera, effectively allowing Pfizer to finalize the acquisition.
A key asset in Metsera’s portfolio is MET-097i, an injectable GLP-1 treatment currently in phase 2b testing. The drug is notable for its potential, as it may only require dosing once a month. For Pfizer, acquiring Metsera presents a significant opportunity to penetrate the rapidly expanding obesity market, following previous setbacks in research and development within this area.
The culmination of this bidding war illustrates the fierce competition in the pharmaceutical industry to secure innovative therapies, particularly in markets with high unmet needs like obesity treatment.
